피부사상균성 조진균증 치료 시장 : 시장 규모, 점유율 및 성장률, 산업 분석 - 유형별, 용도별, 지역별 인사이트, 예측(2026-2034년)

Growth Factors of dermatophytic onychomycosis treatment Market

The global dermatophytic onychomycosis treatment market was valued at USD 5.74 billion in 2025. The market is projected to grow from USD 6.17 billion in 2026 to USD 10.99 billion by 2034, exhibiting a CAGR of 7.49% during the forecast period (2026-2034).

North America dominated the market in 2025 with a 44.33% share, supported by a high number of prescriptions, strong reimbursement policies, and widespread adoption of branded topical therapies.

Dermatophytic onychomycosis is a fungal nail infection caused primarily by dermatophytes, accounting for nearly 70%-80% of onychomycosis cases globally. The disease leads to nail discoloration, thickening, and brittleness, significantly impacting patient quality of life. Rising prevalence of diabetes, aging populations, and increasing awareness of nail fungal infections are major contributors to the expanding demand for effective treatment options.

MARKET OVERVIEW

Onychomycosis represents nearly 50% of all nail disorders worldwide, with an estimated 5.5% global population prevalence. The condition is more common in elderly individuals and diabetic patients, creating long-term demand for both topical and oral antifungal therapies. The market is witnessing steady growth due to increased diagnosis rates, improved access to dermatology services, and availability of both prescription and OTC treatment options.

The COVID-19 pandemic temporarily impacted the market due to reduced patient visits and delayed diagnosis. However, post-pandemic recovery has been supported by clinic reopenings, growing teledermatology adoption, and increased patient awareness.

MARKET DYNAMICS

Market Drivers

The rising prevalence of dermatophytic onychomycosis remains the primary driver of market growth. According to Moberg Pharma AB, nearly 10% of the global population suffers from onychomycosis, with 35-40 million cases in the U.S. alone. Additionally, the growing diabetic population significantly increases susceptibility to fungal nail infections.

Another key driver is the increasing demand for safer treatment alternatives. Oral antifungal drugs are associated with liver toxicity, leading physicians to favor topical nail lacquers, particularly for mild-to-moderate infections.

Market Restraints

Lack of awareness and poor treatment adherence are major challenges. Studies indicate adherence rates of only 45% for oral therapies and 24% for topical treatments, largely due to long treatment durations and limited patient education. These factors restrict timely diagnosis and effective treatment, slowing overall market growth.

MARKET TRENDS

Shift Toward Topical Therapies

A major trend in the market is the gradual shift toward topical solutions, including medicated nail paints and lacquers. Products such as Jublia (efinaconazole) and ciclopirox are increasingly preferred due to lower systemic side effects and improved safety profiles. Continuous innovation aimed at enhancing nail bed penetration is further strengthening this trend.

SEGMENTATION ANALYSIS

By Product Type

The market is segmented into tablets and nail paints.

The nail paints segment dominated the market in 2026, accounting for 50.29% market share, driven by rising adoption of topical therapies and strong sales of Jublia.

The tablets segment is expected to grow steadily due to increasing availability of generic oral antifungals such as terbinafine.

By Route of Administration

The topical segment led the market in 2026 with a 50.29% share, supported by increasing R&D investments and FDA approvals for topical antifungal candidates. Oral therapies remain effective but are limited by safety concerns.

By Distribution Channel

Retail pharmacies dominated the market in 2026 with a 40.62% share, owing to high OTC drug sales and expanding pharmacy networks. Online pharmacies are expected to witness strong growth due to convenience and post-pandemic behavioral shifts.

REGIONAL INSIGHTS

North America generated USD 2.54 billion in 2025, driven by high prescription volumes and strong demand for branded products.

Europe is supported by favorable reimbursement policies and increasing use of generics, with onychomycosis prevalence at 4.3%.

Asia Pacific is expected to grow at the fastest CAGR due to rising diabetes prevalence, aging populations, and new product launches in Japan, China, and India.

COMPETITIVE LANDSCAPE

The market is moderately consolidated, led by Bausch Health Companies Inc., primarily due to strong sales of Jublia. Other prominent players include Pfizer Inc., Galderma, GlaxoSmithKline plc, Cipla Inc., and Kaken Pharmaceuticals Co., Ltd. Strategic initiatives such as generic launches, licensing agreements, and geographic expansion are shaping competitive dynamics.

CONCLUSION

The global dermatophytic onychomycosis treatment market is experiencing consistent growth, driven by rising disease prevalence, increasing diabetic and geriatric populations, and growing preference for safer topical therapies. With the market expanding from USD 5.74 billion in 2025 to USD 10.99 billion by 2034, advancements in drug formulation, expanding OTC availability, and improved patient access are expected to support long-term market expansion. Continued innovation, growing awareness, and favorable regulatory developments are likely to strengthen the adoption of dermatophytic onychomycosis treatments during the forecast period.

CAGR CAGR of 7.49% from 2026-2034

Unit Volume (K Units)

Segmentation By Product Type

• Tablets
• Nail Paints

By Route of Administration

• Oral
• Topical

By Type

• Prescribed
• Over-the-Counter (OTC)

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Channels

By Geography

• North America (By Product Type, By Route of Administration, By Type, By Distribution Channel, and By Country)
  • U.S.
  • Canada
• Europe (By Product Type, By Route of Administration, By Type, By Distribution Channel, and By Country/Sub-region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Russia
  • Rest of Europe
• Asia Pacific (By Product Type, By Route of Administration, By Type, By Distribution Channel, and By Country/Sub-region)
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • Southeast Asia
  • Rest of Asia Pacific

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Epidemiology: Dermatophytic Onychomycosis, Key Countries/ Regions, 2025
• 4.2. Pipeline Analysis, By Key Players
• 4.3. New Product Launches, By Key Players
• 4.4. Key Industry Developments - Mergers, Acquisitions and Partnerships
• 4.5. Impact of COVID-19 on the Market

5. Global Dermatophytic Onychomycosis Treatment Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product Type
  • 5.1.1. Tablets
  • 5.1.2. Nail Paints
• 5.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.2.1. Oral
  • 5.2.2. Topical
• 5.3. Market Analysis, Insights and Forecast - By Type
  • 5.3.1. Prescribed
  • 5.3.2. Over-the-Counter (OTC)
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital Pharmacies
  • 5.4.2. Retail Pharmacies
  • 5.4.3. Online Channels
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Rest of World

6. North America Dermatophytic Onychomycosis Treatment Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product Type
  • 6.1.1. Tablets
  • 6.1.2. Nail Paints
• 6.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.2.1. Oral
  • 6.2.2. Topical
• 6.3. Market Analysis, Insights and Forecast - By Type
  • 6.3.1. Prescribed
  • 6.3.2. Over-the-Counter (OTC)
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Hospital Pharmacies
  • 6.4.2. Retail Pharmacies
  • 6.4.3. Online Channels
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Dermatophytic Onychomycosis Treatment Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product Type
  • 7.1.1. Tablets
  • 7.1.2. Nail Paints
• 7.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.2.1. Oral
  • 7.2.2. Topical
• 7.3. Market Analysis, Insights and Forecast - By Type
  • 7.3.1. Prescribed
  • 7.3.2. Over-the-Counter (OTC)
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Hospital Pharmacies
  • 7.4.2. Retail Pharmacies
  • 7.4.3. Online Channels
• 7.5. Market Analysis, Insights and Forecast - By Countries/ Sub-region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Spain
  • 7.5.5. Italy
  • 7.5.6. Scandinavia
  • 7.5.7. Russia
  • 7.5.8. Rest of Europe

8. Asia Pacific Dermatophytic Onychomycosis Treatment Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product Type
  • 8.1.1. Tablets
  • 8.1.2. Nail Paints
• 8.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.2.1. Oral
  • 8.2.2. Topical
• 8.3. Market Analysis, Insights and Forecast - By Type
  • 8.3.1. Prescribed
  • 8.3.2. Over-the-Counter (OTC)
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Hospital Pharmacies
  • 8.4.2. Retail Pharmacies
  • 8.4.3. Online Channels
• 8.5. Market Analysis, Insights and Forecast - By Countries/ Sub-region
  • 8.5.1. Japan
  • 8.5.2. China
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. New Zealand
  • 8.5.6. Southeast Asia
  • 8.5.7. Rest of Asia Pacific

9. Rest of World Dermatophytic Onychomycosis Treatment Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product Type
  • 9.1.1. Tablets
  • 9.1.2. Nail Paints
• 9.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.2.1. Oral
  • 9.2.2. Topical
• 9.3. Market Analysis, Insights and Forecast - By Type
  • 9.3.1. Prescribed
  • 9.3.2. Over-the-Counter (OTC)
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Hospital Pharmacies
  • 9.4.2. Retail Pharmacies
  • 9.4.3. Online Channels

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2025)
• 10.2. Company Profiles
  • 10.2.1. GlaxoSmithKline plc
    • 10.2.1.1. Overview
    • 10.2.1.2. Products
    • 10.2.1.3. SWOT analysis
    • 10.2.1.4. Recent Developments
    • 10.2.1.5. Strategies
    • 10.2.1.6. Financials (Based on Availability)
  • 10.2.2. Pfizer Inc.
    • 10.2.2.1. Overview
    • 10.2.2.2. Products
    • 10.2.2.3. SWOT analysis
    • 10.2.2.4. Recent Developments
    • 10.2.2.5. Strategies
    • 10.2.2.6. Financials (Based on Availability)
  • 10.2.3. Galderma
    • 10.2.3.1. Overview
    • 10.2.3.2. Products
    • 10.2.3.3. SWOT analysis
    • 10.2.3.4. Recent Developments
    • 10.2.3.5. Strategies
    • 10.2.3.6. Financials (Based on Availability)
  • 10.2.4. Cipla Inc.
    • 10.2.4.1. Overview
    • 10.2.4.2. Products
    • 10.2.4.3. SWOT analysis
    • 10.2.4.4. Recent Developments
    • 10.2.4.5. Strategies
    • 10.2.4.6. Financials (Based on Availability)
  • 10.2.5. Janssen Pharmaceuticals, Inc.
    • 10.2.5.1. Overview
    • 10.2.5.2. Products
    • 10.2.5.3. SWOT analysis
    • 10.2.5.4. Recent Developments
    • 10.2.5.5. Strategies
    • 10.2.5.6. Financials (Based on Availability)
  • 10.2.6. Kaken Pharmaceuticals Co., Ltd.
    • 10.2.6.1. Overview
    • 10.2.6.2. Products
    • 10.2.6.3. SWOT analysis
    • 10.2.6.4. Recent Developments
    • 10.2.6.5. Strategies
    • 10.2.6.6. Financials (Based on Availability)